DELOS nanovesicle-based thermosensitive hydrogels for extended subcutaneous delivery

Alba Córdoba – Technology Transfer & Business Development Director, Nanomol Technologies; Carla Castellar-Álvarez – Scientific Manager, Nanomol Technologies; Lidia Ferrer-Tasies – R&D Director, Nanomol Technologies; Elisabet Gonzalez-Mira – CSIC Researcher, ICMAB-CSIC; Santi Sala – CEO, Nanomol Technologies; Nora Ventosa – CSIC Associated and CEO-CSO at DELBIOS Pharmaceuticals, ICMAB-CSIC/Nanomol Technologies

Introduction:

The subcutaneous route has gained increasing interest for extended drug delivery in chronic therapies, as it allows prolonged exposure, reduced dosing frequency, fewer side effects, and improved patient compliance. In situ–forming thermosensitive hydrogels, particularly when combined with versatile nanocarriers such as DELOS nanovesicles (DELOS-NV), capable of encapsulating therapeutics from small molecules to biologics, offer a promising strategy to create extended-release depots, enabling self-administration, avoiding first-pass metabolism, and overcoming poor oral bioavailability.